Abiopharma

🔍 Kashyap Rana (Executive)

Company: Groupon, Inc. (GRPN)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 77,625 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 225,625.00 | transaction_form_type: 4
• Sold 35,973 shares of Common Stock at $14.89 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 189,652.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By custodial account for child | shares_owned_after: 15,000.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By custodial account for child | shares_owned_after: 10,000.00 | Footnotes: F2
• Sold 77,625 shares of Performance Share Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 158,391.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Acquired 63,870 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 63,870.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6
• Acquired 63,870 shares of Performance Share Units (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 63,870.00 | transaction_form_type: 4 | Footnotes: F3, F7, F7

Footnotes:

• F1: Shares withheld to satisfy the mandatory tax withholding requirement upon the vesting of performance share units ("PSUs"). This is not an open market sale of securities.
• F2: Represents shares held in a custodial account for the benefit of the Reporting Person's child. The Reporting Person is the custodian of such account. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
• F3: Each PSU represents a contingent right to receive one share of Groupon, Inc. (the "Issuer") Common Stock.
• F4: The number of shares of Common Stock that will be acquired upon the vesting of the PSUs is contingent upon the: achievement of pre-established stock price hurdles over a three-year performance period beginning on May 1, 2024 and ending on May 1, 2027; and achievement of continued service conditions measured on each of May 1, 2025, May 1, 2026, and May 1, 2027. The PSUs shall vest immediately upon certification of the achievement of both conditions by the Compensation Committee of the Issuer's Board of Directors.
• F5: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Common Stock.
• F6: The RSUs will vest in three equal tranches (one third on each of May 1, 2027, May 1, 2028, and May 1, 2029), subject to continued service and a year-end performance review modifier of 0% to 300% per tranche.
• F7: The number of shares of Common Stock that will be acquired upon the vesting of the PSUs is contingent upon the Company's relative TSR vs. Russell 2000 Index over a three-year performance period (May 1, 2026 to May 1, 2029). The PSUs will cliff vest on May 1, 2029, ranging from 0% (at or below 50th percentile) to 300% (at or above 90th percentile). In the event of negative TSR, payout is capped at 100%.
• REMARKS: Exhibit 24 - Power of Attorney